araag2/HINT huggingface dataset:
Clinical trial NCT00702806 (phase 2, status: completed)
Conditions: infertility, in vitro fertilization
ICD codes: N46.8, N46.9, N97.9, N97.0, N97.1, N97.2, N97.8, N98.2
Drugs: org 36286, puregon®, orgalutran®, pregnyl®
SMILES: CCNC(NCC)=NCCCC[C@@H](NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CC=CN=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC2=CC=CC=C2C=C1)NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN=C(NCC)NCC)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Females of couples with an indication for COH and IVF or IVF/ICSI;

          -  Body mass index (BMI) >=18 and <=29 kg/m^2;

          -  Normal menstrual cycle length: 24-35 days;

          -  Ejaculatory sperm;

        Exclusion Criteria:

          -  History of/or current endocrine abnormality such as polycystic ovary syndrome (PCOS),
             or polycystic ovaries according to ultrasound scan (USS), (treated) hyperprolactinemia
             or evidence of ovarian dysfunction;

          -  More than three unsuccessful COH cycles for IVF since the last established ongoing
             pregnancy (if applicable);

          -  History of non- or low ovarian response to FSH/human menopausal gonadotropin (hMG)
             treatment;

          -  Any clinically relevant hormone value outside the reference range during the early
             follicular phase (menstrual Cycle Day 2-7) as measured by the local laboratory (FSH,
             luteinizing hormone [LH], estradiol [E2], progesterone [P], total testosterone [T],
             thyroid stimulating hormone [TSH], and prolactin);

          -  Any clinically relevant abnormal laboratory value;

          -  Any ovarian and/or abdominal abnormality interfering with ultrasound examination;

          -  Contraindications for the use of gonadotropins (e.g. tumors, pregnancy/lactation,
             undiagnosed vaginal bleeding, hypersensitivity, ovarian cysts);

          -  Epilepsy, diabetes, cardiovascular, gastro-intestinal, hepatic, renal, pulmonary, or
             abdominal disease;

          -  History or presence of alcohol or drug abuse within 12 months prior to signing
             informed consent;

          -  Hypersensitivity to Orgalutran® or any of its components;

          -  Administration of investigational drugs within three months prior to screening.

          -  Use of hormonal preparations within one month prior to the start of Org 36286 with the
             exception of thyroid medication.
Clinical trial NCT00101127 (phase 2, status: completed)
Conditions: sarcoma
ICD codes: C96.A, C46.9, C96.22, C46.0, C46.2, C92.31, C92.32
Drugs: docetaxel, gemcitabine hydrochloride
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed uterine leiomyosarcoma

               -  Advanced, persistent, or recurrent disease

               -  Documented disease progression

          -  Measurable disease

               -  At least 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques
                  OR ≥ 10 mm by spiral CT scan

          -  At least 1 target lesion

               -  Tumors within a previously irradiated field are considered nontarget lesions

          -  Ineligible for higher priority GOG protocols (i.e., any active phase III GOG protocol
             for the same patient population)

        PATIENT CHARACTERISTICS:

        Age

          -  Adult

        Performance status

          -  GOG 0-2

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Absolute neutrophil count ≥ 1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

        Hepatic

          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)

          -  AST ≤ 2.5 times ULN

          -  Alkaline phosphatase ≤ 2.5 times ULN

        Renal

          -  Creatinine ≤ 1.5 times ULN

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No neuropathy (sensory or motor) > grade 1

          -  No other invasive malignancy within the past 5 years except nonmelanoma skin cancer

          -  No active infection requiring antibiotics

          -  No known hypersensitivity to E. coli-derived proteins

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  No prior cytotoxic chemotherapy for the malignancy

        Endocrine therapy

          -  At least 1 week since prior hormonal therapy for the malignancy

          -  Concurrent hormone replacement therapy allowed

        Radiotherapy

          -  See Disease Characteristics

          -  Recovered from prior radiotherapy

        Surgery

          -  Recovered from prior surgery

        Other

          -  Recovered from all other prior therapy

          -  No prior cancer treatment that would preclude study treatment

          -  No concurrent amifostine or other protective agents
Clinical trial NCT00464919 (phase 2, status: completed)
Conditions: hepatocellular carcinoma
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: sorafenib, tegafur/uracil (ufur®)
SMILES: CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1, FC1=CN(C2CCCO2)C(=O)NC1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Age > 18 years;

          -  ECOG PS 0-2;

          -  Histologically or cytologically documented unresectable and/or metastatic HCC;

          -  Measurable disease by RECIST criteria;

          -  Previous local therapy completed > 6 weeks;

          -  Any acute toxicity (CTC-AE) < grade 1;

          -  Child-Pugh A;

          -  Liver transaminases ≤ 5 x ULN;

          -  Albumin ≥ 2.8 g/dl;

          -  Serum total bilirubin ≤ 3 mg/dl;

          -  INR ≤ 2.3 or PT ≤ 6 seconds above control;

          -  WBC ≥ 3,000/µl;

          -  ANC ≥ 1,500/µl;

          -  Platelets ≥ 100,000/µl;

          -  Hb ≥ 8.5 g/dl;

          -  Creatinine ≤ 1.5 x ULN; AND

          -  Amylase and lipase < 1.5 x ULN

        Exclusion Criteria:

          -  Metastatic brain/leptomeningeal tumors;

          -  Prior or concomitant systemic anti-cancer treatment for HCC, including:

               -  Systemic chemotherapy (TACE is allowed)

               -  Immunotherapy

               -  Hormonal therapy (hormonal therapy used for supportive used is allowed)

               -  Raf-kinase inhibitors

               -  MEK inhibitors

               -  Farnesyl transferase inhibitors

               -  VEGF/VEGFR- inhibitors or other anti-angiogenesis agents

               -  Investigational anti-cancer agents

          -  Severe and/or uncontrolled medical conditions:

               -  Uncontrolled high blood pressure

               -  History of poor compliance with anti-hypertensive agents

               -  Active or uncontrolled infection

               -  Unstable angina

               -  CHF

               -  MI or CVA < 6 months

               -  GI bleeding < 30 days

               -  Unable to take oral medications

          -  Severe renal impairment which requires dialysis; proteinuria > grade 2;

          -  BMT or stem cell rescue < 4 months; organ transplant;

          -  HIV infection;

          -  Major surgical procedure, open biopsy, or significant traumatic injury < 4 weeks or
             those who receive minor surgical procedures (e.g. core biopsy or fine needle
             aspiration) within 2 weeks;

          -  Receive central venous line placement within 7 days;

          -  Patients who anticipate receiving major surgery during the course of the study;

          -  Use rifampin, St. John's Wort [Hypericum perforatum];

          -  Patients taking narrow therapeutic index medications will be monitored closely. These
             include warfarin, phenytoin, quinidine, carbamazepine, phenobarbital, cyclosporine,
             and digoxin; OR

          -  Patients for whom tegafur is contra-indicated
Clinical trial NCT00172094 (phase 2, status: completed)
Conditions: migraine headache
ICD codes: G43.B1, G43.D1, G43.B0, G43.D0, G43.A1, G43.411, G43.419
Drugs: nps 1776 (800 mg), placebo, nps 1776 (400 mg)
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Diagnosis of migraine for at least a year prior to screening.

          2. Experiences 2-10 migraine headaches per month (with at least 24 hours between
             episodes) and no more than 15 headache days per month in the 3 months prior to
             screening.

          3. Ability and willingness to arrive at the investigator's center within 1 hour (±5 min)
             of migraine pain onset (defined as pain that is consistent with the subject's usual
             migraine and is of at least moderate severity).

          4. Ability and willingness to abstain from taking medications not allowed by the protocol
             and to meet phone and check-in criteria.

          5. Ability and willingness to undergo a comprehensive urine toxicology screen for both
             licit and illicit drugs.

          6. Ability and willingness to complete a migraine-history diary from screening to
             treatment with study drug and a migraine-treatment diary from discharge through the
             remainder of the 24-hour period following study-drug treatment.

        Exclusion Criteria:

          1. Unstable or uncontrolled significant metabolic, hepatic, renal, hematological,
             pulmonary, gastrointestinal, urological, neurological (except migraine headaches), or
             psychiatric disorders.

          2. Severe or acute cardiovascular or cerebrovascular disease, uncontrolled hypertension,
             or basilar or hemiplegic migraines.

          3. History of hypersensitivity, allergies, or nonresponse to valproic acid.

          4. Have taken VPA or other AED in the 30 days prior to screening, or are taking a
             migraine prophylaxis treatment other than a stable dose of propranolol or tricyclic
             antidepressant.

          5. Migraine attacks that in the investigator's opinion are associated with intractable
             nausea and/or vomiting.

          6. Any acute or chronic condition that in the investigator's opinion would limit the
             subject's ability to complete and/or participate in this clinical study or would place
             the subject at increased risk.

          7. Have newly started or changed the dose of either feverfew or magnesium (above 200 mg,
             the amount in common daily supplements) within 3 months prior to screening.
Clinical trial NCT01107392 (phase 2, status: completed)
Conditions: benign prostatic hyperplasia
ICD codes: N40.0, N40.1
Drugs: botulinum toxin type a, normal saline
SMILES: O
Eligibility criteria:

        Inclusion Criteria:

          -  Clinical enlargement of the prostate gland

          -  Body weight ≥ 50 kg or 110 lbs

        Exclusion Criteria:

          -  History of chronic prostatitis

          -  History of two or more urinary tract infections in the past year or one in the last 6
             months

          -  History of bladder stones

          -  History of previous prostate surgery

          -  History of bladder cancer or prostate cancer

          -  Any previous or current usage of botulinum toxin therapy of any serotype for any
             urological condition

          -  Botulinum toxin therapy of any serotype for any non-urological condition or usage
             (e.g., cosmetic) during the previous 12 weeks prior to study entry
Clinical trial NCT00706719 (phase 2, status: completed)
Conditions: secondary hypogonadism
ICD codes: D75.1, E26.1, N91.1, N91.4, N94.5, A51.41, A51.43
Drugs: 25 mg androxal, testim 1%
SMILES: CCN(CC)CCOC1=CC=C(C=C1)C(=C(Cl)C1=CC=CC=C1)C1=CC=CC=C1, [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Healthy adult males between 21 and 60 years of age who have been diagnosed with AIHH.

          -  Subjects must have been treated with a topical testosterone replacement therapy
             (typically AndroGel® or Testim®) for at least 6 months at enrollment and for not more
             than 2 years.

        Exclusion Criteria:

          -  A history of idiopathic infertility due to primary hypogonadism, testicular failure,
             Kallmann's syndrome or any other infertility condition.

          -  Subjects demonstrating any clinically significant medical condition rendering the
             subjects infertile or marginally fertile other than AIHH.

          -  Men with a history of, known, or suspected prostate disease not ruled out by a
             prostate biopsy, or a prostate specific antigen (PSA)>3.6 or clinical suspicion of
             current prostate disease.

          -  Men with a hematocrit in excess of 50 % or hemoglobin >17 g/dl
Clinical trial NCT01321463 (phase 2, status: completed)
Conditions: pulmonary disease, chronic obstructive
ICD codes: J44.9, J44.1, J44.0
Drugs: ph-797804, placebo
SMILES: CNC(=O)C1=CC=C(C)C(=C1)N1C(C)=CC(OCC2=C(F)C=C(F)C=C2)=C(Br)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female subjects between, and including, the ages of 40 and 80 years.

          -  Subjects with a diagnosis, for at least 6 months, of moderate to severe COPD (GOLD)
             and who meet the criteria for Stage II-III disease.

          -  Subjects must have a smoking history of at least 10 pack-years and be current smokers
             or ex-smokers that gave up > 6 months ago.

          -  Subjects must be treated with a LABA/ICS combination for at least 1 month prior to
             screening.

        Exclusion Criteria:

          -  A COPD exacerbation requiring treatment with oral steroids or hospitalization for the
             treatment of COPD within 3 months of screening.

          -  History or presence of significant cardiovascular disease.

          -  ECG abnormalities.

          -  Significant concomitant clinical disease that could interfere with the conduct, safety
             or interpretation of results of this study.

          -  Evidence of organ or blood disorders.
Clinical trial NCT00038701 (phase 2, status: terminated)
Conditions: pancreatic neoplasms
ICD codes: C25.3
Drugs: tnp-470
SMILES: [H][C@]1(CC=C(C)C)O[C@]1(C)[C@@]1([H])[C@]([H])(OC)[C@@]([H])(CC[C@]11CO1)OC(=O)NC(=O)CCl
Reason stopped: 
    slow accrual.
  
Eligibility criteria:

        Patients must have cytologic or histologic proof of adenocarcinoma of the pancreas.

        All patients must be staged with a physical exam and CXR. Patients must have locally
        advanced disease defined as tumor extension to the celiac axis or SMA, or occlusion of the
        SMPV confluence (on contrast-enhanced CT). There must be no radiographic evidence of
        metastatic disease.

        Patients must have had no prior chemotherapy or irradiation.

        Patients must have a baseline Karnofsky performance status of at least 60.

        Patients must have adequate bone marrow reserve platelet count >100,000/mL, hemoglobin>9
        g/dL, absolute granulocyte count must be >1,500 cells/mm3,serum creatinine must be <1.6
        mg/dL. Serum bilirubin must be less than 5 mg/dL prior to therapy with endoscopic or
        percutaneous drainage if necessary.

        Patients must have estimated life expectancy of at least 12 weeks.

        Patients must be at least 18 years of age. There will be no upper age restriction.

        Female patients must have had childbearing potential terminated by surgery, radiation, or
        menopause, or attenuated by use of an approved contraceptive method (intrauterine device
        [IUD], birth control pills, barrier device, or abstinence.

        Patients cannot have hepatic or peritoneal metastases detected by ultrasound (US), CT scan,
        or laparotomy prior to chemoradiation.

        Before receiving external beam irradiation, patients should be able to maintain adequate
        oral nutrition (90% to 100% of estimated need of calories and protein) and be free of
        significant nausea and vomiting.

        Patients should have bilateral renal function, as determined on excretory urogram (IVP) or
        abdominal CT, or >2/3 of one functioning kidney must be able to be shielded from the
        radiation beam.

        Patients must have no fever or evidence of infection or other coexisting medical condition
        that would preclude protocol therapy.

        Patients must sign an informed consent form
Clinical trial NCT00376961 (phase 2, status: completed)
Conditions: lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: bortezomib, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed mantle cell lymphoma (MCL) meeting the following criteria:

               -  Stage III-IV or bulky stage II disease

               -  Confirmation of positivity for the following phenotypes by immunohistochemistry
                  or flow cytometry:

                    -  Cluster of differentiation antigen 19 (CD19) (or CD20)

                    -  Cyclin D1 OR evidence of t(11;14) translocation by cytogenetic analysis or
                       fluorescent in situ hybridization

          -  Newly diagnosed, previously untreated disease

          -  Bidimensionally measurable disease by conventional techniques

               -  No nonmeasurable disease only

          -  Adequate tumor tissue from original diagnostic specimen available

               -  Tissue obtained by needle aspiration or cytology not allowed

          -  No clinical evidence of central nervous system (CNS) involvement by lymphoma

          -  Co-registration on protocols SWOG-8947 and SWOG-8819 is strongly encouraged

        PATIENT CHARACTERISTICS:

          -  Zubrod performance status 0-2

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No peripheral neuropathy ≥ grade 2

          -  No hypersensitivity to bortezomib, boron, or mannitol

          -  No other prior malignancy except for adequately treated basal cell or squamous cell
             skin cancer, in situ cervical cancer, adequately treated stage I or II cancer for
             which the patient is currently in complete remission, or any other cancer for which
             the patient has been disease free for the past 5 years

          -  HIV negative

        PRIOR CONCURRENT THERAPY:

          -  No prior chemotherapy, radiotherapy, or antibody therapy for lymphoma

          -  More than 14 days since prior investigational drugs
Clinical trial NCT01138163 (phase 2, status: completed)
Conditions: non-small-cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: docetaxel plus bavituximab or placebo
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Adults over age 18 years of age with a life expectancy of at least 3 months.

          -  Histologically or cytologically confirmed stage IIIB or stage IV non squamous
             non-small-cell lung cancer (NSCLC) who have progressed after 1 chemotherapy regimen.

          -  Measurable disease by Response Evaluation Criteria In Solid Tumors (RECIST, Version
             1.1) on cross-sectional imaging that is at least 2 cm in longest diameter.

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2.

          -  Adequate hematologic, renal, and hepatic function.

          -  PT/INR ≤ 1.5 × ULN; aPTT time ≤ 1.5 × ULN.

          -  New York Heart Association classification I or II

        Exclusion Criteria:

          -  Squamous, small cell, or mixed histology.

          -  Known history of bleeding diathesis or coagulopathy.

          -  Cavitary tumors or tumors invading or abutting large blood vessels.

          -  Bleeding: Clinically significant bleeding such as gross hematuria, GI bleeding and
             hemoptysis within 12 months of Screening.

          -  Venous thromboembolic events within 6 months of screening.

          -  Ongoing therapy with oral or parenteral anticoagulants.

          -  Concurrent estrogens, anti-estrogens or progesterone compounds.

          -  Radiotherapy within 2 weeks or major surgery within 4 weeks preceding Study Day 1.

          -  Symptomatic or clinically active brain metastases.

          -  Symptomatic coronary artery disease, cerebrovascular accident, transient ischemic
             attack, myocardial infarction or unstable angina pectoris within 6 months of
             screening.

          -  Grade 2 or higher peripheral neuropathy
Clinical trial NCT00231868 (phase 2, status: completed)
Conditions: uterine cancer
ICD codes: C57.4, D28.2
Drugs: carboplatin and paclitaxel and pelvic radiation therapy, carboplatin and paclitaxel and radiation therapy
SMILES: [H][N]([H])([H])[Pt]1(OC(=O)C2(CCC2)C(=O)O1)[N]([H])([H])[H], [H][N]([H])([H])[Pt]1(OC(=O)C2(CCC2)C(=O)O1)[N]([H])([H])[H]
Eligibility criteria:

        Inclusion Criteria:

          1. Histologically documented uterine papillary serous carcinoma (UPSC) with no visible
             residual disease.

          2. Surgical staging to include total abdominal hysterectomy, bilateral
             salpingo-oophorectomy, peritoneal washings, and lymph node samplings.

          3. Age > 18 years.

          4. ECOG performance status of < 2.

          5. Written voluntary informed consent.

        Exclusion Criteria:

          1. Patient has impairment of hepatic, renal or hematologic function as defined by the
             following baseline laboratory values:

               1. Serum SGOT and /or SGPT > 2.5 times the institutional upper limit of normal

               2. Total serum bilirubin > 1.5 mg/dl

               3. History of chronic or active hepatitis

               4. Serum creatinine > 2.0 mg/dl

               5. Platelets < 100,000/mm3

               6. Absolute neutrophil count (ANC) < 1500/mm3

               7. Hemoglobin < 8.0 g/dl (the patient may be transfused prior to study entry)

          2. Patient has severe or uncontrolled concurrent medical disease (eg. uncontrolled
             diabetes, unstable angina, myocardial infarction within 6 months, congestive heart
             failure, etc.)

          3. Patient has been treated with myelosuppressive chemotherapy within three weeks prior
             to study entry.

          4. Patient with any prior chemotherapy or radiotherapy for pelvic malignancy.

          5. Patients with dementia or altered mental status that would prohibit the giving and
             understanding of informed consent at the time of study entry.